Physician profile
Richard Ortiz
NPI 1467410290
$2,502.65
in general payments reported to CMS, 2019-2025
36 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $92.92 · 2021: $360 · 2022: $341 · 2023: $278 · 2024: $145 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $693.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $239.31 | 2019-2023 | |
| Glaxosmithkline, LLC. | $232.24 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbvie INC. | $226.06 | 2019-2023 | |
| Lilly USA, LLC | $176.66 | 2019-2025 | Mounjaro, Kisunla |
| Astrazeneca Pharmaceuticals LP | $137.51 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.52 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.52 | 2019-2021 | |
| Amgen INC. | $111.79 | 2019-2025 | Otezla, Repatha |
| Abbott Laboratories | $111.42 | 2019-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $90.03 | 2019-2024 | |
| Gilead Sciences, INC. | $80.76 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.28 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $73.04 | 2019-2023 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $72.86 | 2019 | |
| Nevro Corp. | $55.60 | 2022-2024 | Senza |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $53.06 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $47.30 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.58 | 2022 | |
| Amarin Pharma, INC. | $40.73 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.32 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $37.45 | 2019-2021 | |
| Corcept Therapeutics | $31.26 | 2024 | Korlym |
| Genentech USA, INC. | $28.78 | 2019-2020 | |
| Daiichi Sankyo INC. | $28.15 | 2024-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $26.77 | 2019 | |
| Ironwood Pharmaceuticals, INC | $26.68 | 2019-2022 | |
| Kyowa Kirin, INC. | $22.87 | 2025 | |
| Recor Medical INC | $21.73 | 2025 | Paradise Ultrasound Renal Denervation System |
| Supernus Pharmaceuticals, INC. | $21.03 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $18.82 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.52 | 2025 | |
| Ardelyx, INC. | $17.36 | 2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $14.17 | 2022 | |
| Eisai INC. | $14.13 | 2025 | |
| Boston Scientific Corporation | $13.84 | 2024 | Watchman Flx |
| Antares Pharma, INC. | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.